New Insight of Non-small Cell Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 15928
Special Issue Editor
Special Issue Information
Dear Colleagues,
Non-small cell lung cancer is currently the most common malignant neoplasm in the world and the leading cause of cancer deaths worldwide. In more than half of the cases, non-small cell lung cancer is detected after the disease has already progressed. For these patients, chemotherapy is usually the first-line treatment. Traditionally, several platinum-based drugs have been used as the standard first-line treatment for non-small cell lung cancer. However, the development of molecular targeted therapies and immune checkpoint inhibitors has dramatically changed the treatment of non-small cell lung cancer. In addition to early-stage diseases, radiotherapy and surgery are also indicated for advanced diseases with certain conditions. In addition, comorbidities such as interstitial lung disease and metastatic lesions require careful consideration to select treatment option. In this Special Issue, we would like to discuss recent topics related to non-small cell lung cancer.
Dr. Nobuyuki Horita
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung carcinoma
- biomarkers
- immune checkpoint inhibitors
- randomized controlled trial
- evidence-based medicine
- co-morbidities